Advertisement

Topics

NPS+ Renal Cell Carcinoma EU5 2018 [Report Updated: 01022018] Prices from USD $2655

01:44 EDT 14 Mar 2018 | BioPortfolio Report Blog




Why are some EU5 RCC brands standing out more than others?


There are various options available to EU5 oncologists to treat renal cell carcinoma RCC. Clearly some of these options are achieving greater levels of loyalty and satisfaction than others but why? What are the key factors driving physician choice and how does each of the leading brands compare to its competitors?


NPS+ RCC EU5 gives a unique insight into the overall brand health of 9 leading treatments for RCC currently being used in Europe. 150 oncologists were surveyed on key issues including brand messaging, prescribing behaviour and satisfaction levels. The results provide valuable insight for brand marketers seeking new ways to stand out.


Request sample pages






Top Takeaways


Two brands lead the way, and the rest don't even get close. Of the 9 brands included in the survey, two brands lead the way and are 14 points ahead of third place. But 6/10 brands don't even achieve a positive NPS. Which ones lead the way, and where are the key fights for lower places?

Brand loyalty is difficult to come by. Loyalty scores of less than 3 indicate low loyalty, and none of the brands surveyed managed to score above this magic number. Is clinical differentiation really that low?

Satisfaction scores lower than the US. EU5 physicians aren't as satisfied as theiry US counterparts, it would seem. What's causing this low level of satisfaction, and is it being felt across all brands, or just a small selection?

Is there a dominant brand message? Find out which messages are resonating with physicians, and take your brand's positioning strategy to another level.

In their own words. What do doctors say each brand means to them? For example, which brand is described as a reliable, safe reference treatment' and which brand is dubbed as too aggressive'?


Insight into 9 RCC Treatments


Afinitor everolimus; Novartis

Avastin bevacizumab; Roche

Cabometyx cabozantinib; Exelixis

Inlyta axitinib; Pfizer

Nexavar sorafenib; Bayer/Amgen

Opdivo nivolumab; BristolMyers Squibb

Sutent sunitinib; Pfizer

Torisel temsirolimus; Pfizer

Votrient pazopanib; Novartis



Explore Important Brand Loyalty Issues


NPS+ RCC EU5 offers valuable insight into brand loyalty from the perspective of those currently prescribing treatments for RCC to patients. You'll discover:


Exactly how satisfied the European market is.

How loyal doctors are to your brand.

How many other brands your Promoters recommend.

Which other brands your Promoters and Detractors recommend.

How much market share your brand has among Promoters and Detractors.

How much market share you stand to gain by converting Detractors into Promoters.

Which messages Promoters, Passives and Detractors associate with your brand.

Your brand DNA: what doctors really think of your brandin their own words.


A Report Based on Expert Knowledge


We surveyed 150 EUbased oncologists chosen from the largest community of validated physicians in the world. We conducted the survey between January 1020, 2018.


What is Net Promoter Score?


NPS is a customer loyalty metric developed by and a registered trademark of Fred Reichheld, Bain Company, and Satmetrix. It was introduced by Reichheld in his 2003 Harvard Business Review article One Number You Need to Grow.


How does NPS work?


NPS measures overall brand satisfaction and loyalty by asking one simple question:

"How likely are you to recommend this brand to a colleague?"

Responses given on a scale of 0 not at all likely to 10 extremely likelyare used to classify respondents into 3 categories:


Detractors are those who answer 0 6.

Passives are those who answer 7 8.

Promoters are those who answer 9 10.


How is NPS calculated?


The percentage of detractors the percentage of promoters = NPS.


For example, 25% Promoters, 55% Passives and 20% Detractors give you an NPS of +5.


NPS can range from 100 everybody is a Detractor to +100 everybody is a Promoter. The higher the score the healthier the brand.


What is FirstView NPS+?


NPS+ turns your Net Promoter Score into actionable information by answering key questions about brand loyalty.


Each NPS+ report examines doctors' relationships with the brands used to treat a major disease areameasuring brand loyalty and showing you how it affects your market share. NPS+ also examines brand DNA, revealing in doctors' own words what brands mean to them.


Instead of one simple metric, NPS+ gives you a detailed picture of brand health that highlights areas for improvement, and helps you see exactly what steps you need to take next.


MONEY BACK GUARANTEE!


At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.


About FirstWord


FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.


FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering uptotheminute pharma news, insight, analysis and expert views of importance to your company's success.

FirstWord Reports deliver timely, needtoknow intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.


FirstWord Reports deliver timely, needtoknow intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.


Learn more at www.firstwordgroup.com.

Original Article: NPS+ Renal Cell Carcinoma EU5 2018 [Report Updated: 01022018] Prices from USD $2655

NEXT ARTICLE

More From BioPortfolio on "NPS+ Renal Cell Carcinoma EU5 2018 [Report Updated: 01022018] Prices from USD $2655"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Renal Cell Carcinoma
Renal cell cancer (renal adenocarcinoma or hypernephroma) is the most common type of kidney cancer in adults. More than 8 in every 10 (80%) kidney cancers diagnosed in the UK are this type.  In renal cell cancer the cancerous cells start in the lini...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...